Back to top
more

Insulet (PODD)

(Delayed Data from NSDQ)

$173.42 USD

173.42
630,543

+3.15 (1.85%)

Updated May 2, 2024 04:00 PM ET

After-Market: $174.50 +1.08 (0.62%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (151 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

Universal Health (UHS) Up 17% in 3 Months: More Growth Ahead?

Universal Health (UHS) is well-poised for growth on the back of the resumption of elective procedures, acquisitions and solid operating cash flows.

Henry Schein (HSIC) Enters Orthopedic Market With New Buyout

Henry Schein's (HSIC) recent deals will position it as a prominent producer and supplier in the orthopedic market's Foot and Ankle, Hand and Wrist extremity sectors.

Exact Sciences' (EXAS) Solid Cologuard Sales, Innovation Aid

Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is offering therapy selection tests for patients with advanced cancer.

Myriad Genetics' (MYGN) New Platform to Advance Cancer Care

Myriad Genetics' (MYGN) new MCRR platform advances patient care by combining structured clinical data with genetic and genomic results.

Bruker (BRKR) Installs First 1.2 GHz NMR at Ohio University

Bruker (BRKR) 1.2 GHz AVANCE NMR spectrometer is cutting-edge equipment capable of performing high-resolution liquid and solid-state NMR studies.

Bio-Rad (BIO) Faces Soft Industry-wide Demand, Macro Woes

Bio-Rad's (BIO) margin performance suffers due to elevated raw material costs, increased logistics costs and higher employee-related expenses.

Venus Concept (VERO) Expands Global Reach With New Partnerships

Venus Concept (VERO) expects its deals to fetch continued success in both the United Kingdom and India.

Quest Diagnostics (DGX) Unveils the 88-Compound NPS Test Panel

Quest Diagnostics (DGX) launches the new 88-Compound NPS test panel to address the changing drug epidemic.

Benjamin Rains headshot

How to Find the Best Top-Ranked Stocks to Buy in 2024

Here is how to utilize the Filtered Zacks Rank 5 Stock Screen to help find potentially winning stocks to buy to close out December and throughout 2024.

Here's Why You Should Invest in Penumbra (PEN) Stock Now

Investors are optimistic about Penumbra (PEN), which is led by growth in vascular and neuro businesses.

Align's (ALGN) Invisalign Palatal Expander System Gets FDA Nod

Align's (ALGN) Invisalign Palatal Expander is the company's first direct 3D-printed orthodontic device. It offers a safe, pleasant and clinically effective alternative to traditional palatal expanders.

CVS Health (CVS) New Opportunities Drive Growth, Macro Woes Stay

CVS Health's (CVS) restructuring plan poises it well, along with its strategic buyouts.

SenesTech (SNES) Likely to Expand Into China With New Deal

This partnership provides SenesTech (SNES) with a gateway into one of the largest pest control markets globally, with the support and expertise of Fruit Tree.

Nalak Das headshot

5 Nasdaq Composite Laggards Likely to Gather Pace in 2024

We have narrowed our search to five Nasdaq Composite listed laggards of 2023 with strong potential for 2024. These are: PEP, KHC, WMG, PODD, BGNE.

Charles River's (CRL) Memphis Site Achieves Crucial Approval

Charles River (CRL) reaches an important milestone in cell therapy manufacturing collaboration with Vertex Pharmaceuticals.

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

Investors remain optimistic about Tandem Diabetes (TNDM), backed by the impressive spree of product introductions.

Abbott (ABT) Gains From Global Expansion Amid Macro Woes

Abbott's (ABT) EPD business continues to witness low double-digit growth. It has successfully positioned itself as one of the best-positioned large healthcare companies in emerging markets.

Thermo Fisher (TMO) to Allocate IFA Testing Kits With New Pact

Thermo Fisher (TMO) will continue to meet the evolving needs of laboratories and healthcare professionals by expanding its immunology product portfolio of EliA autoimmune diagnostics.

Quest Diagnostics' (DGX) Haystack Oncology Inks New Deal

Quest Diagnostics' (DGX) wholly owned subsidiary, Haystack Oncology, partners with the Rutgers Cancer Institute of New Jersey.

Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now

Investors continue to be optimistic about IDEXX (IDXX), backed by the strength of the CAG Diagnostics business.

Here's Why You Should Retain Hologic (HOLX) Stock for Now

Investors are optimistic about Hologic (HOLX), which is led by growth with recovery in procedural volumes and acceleration from new business lines.

Here's Why You Should Retain Globus Medical (GMED) Stock Now

Investors are optimistic about Globus Medical (GMED) on growing demand for musculoskeletal devices and its strong solvency position.

Neogen (NEOG) to Advance Feline DNA Testing With New Pact

Neogen's (NEOG) strategic alliance will expand feline DNA testing and strengthen its relationship with the kitty community.

Align's (ALGN) New Launches Aid, Macroeconomic Woes Linger

Align Technology (ALGN) performs digital treatment planning and interpretation for restorative cases worldwide, including Costa Rica, China, Germany, Spain, Poland and Japan, among others.

Align Technologies (ALGN) Secures Updated Medical Device License

Align Technologies' (ALGN) Invisalign Palatal Expander system receives an updated medical device license from Health Canada.